The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

sotalol     N-[4-[1-hydroxy-2-(propan-2...

Synonyms: Sotalolum, Sorine, beta-Cardone, d,l-Sotalol, CHEMBL471, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of sotalol

  • The risk of a recurrence of arrhythmia was significantly lower in patients who received sotalol than in those who received other antiarrhythmic drugs, and the risk was lower in those who had not previously failed to respond to antiarrhythmic drugs than in those who had [1].
  • METHODS: We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone [2].
  • In patients similar to those in this study, if antiarrhythmic-drug therapy is to be used to prevent recurrences of ventricular tachyarrhythmias, treatment with sotalol and assessment of its potential efficacy by Holter monitoring are a reasonable initial strategy [3].
  • As compared with other antiarrhythmic agents, sotalol prevents recurrences of arrhythmia in a higher proportion of patients, particularly among those presenting with ventricular tachycardia and aborted sudden cardiac death [4].
  • Controlled trial of sotalol for one year after myocardial infarction [5].

Psychiatry related information on sotalol

  • In an alternate therapy group (n = 41) of similar patients previously refractory to or intolerant of procainamide, intravenous sotalol prevented inducibility in 32% [6].
  • The effects of sotalol on EEG, sleep, and performance in psychological tests were equivocal and do not yield evidence for CNS activity of sotalol [7].
  • The effects of sotalol on heart rate, blood pressure, EEG, subjective quality of sleep, polygraphically determined sleep pattern, and psychophysiological parameters such as psychomotor performance, memory, perception, vigilance, and general condition were studied and were related to dosage and plasma levels [7].
  • The beta-adrenergic antagonists sotalol, nadolol and timolol (which act at both beta 1- and beta 2-receptors) induce amnesia in the domestic chick when given systemically after a one trial passive avoidance task [8].

High impact information on sotalol

  • METHODS: In a multicenter trial, patients were stratified according to left ventricular ejection fraction (< or =0.30 or >0.30), randomly assigned to double-blind treatment with 160 to 320 mg of sotalol per day (151 patients) or matching placebo (151 patients), and followed for 12 months [9].
  • CONCLUSIONS: Oral sotalol was safe and efficacious in reducing the risk of death or the delivery of a first defibrillator shock whether or not ventricular function was depressed [9].
  • Although initially marketed in the United States for treatment of life-threatening ventricular arrhythmias, sotalol also has demonstrated efficacy in many patients with supraventricular arrhythmias [4].
  • Tachycardia persisted in 14 patients in the lignocaine group and 4 in the sotalol group after 15 min [10].
  • The addition of a low dose of aspirin to sotalol treatment showed significant benefit in terms of cardiovascular events, including a significant reduction in the incidence of first myocardial infarction in patients with symptoms of stable angina pectoris [11].

Chemical compound and disease context of sotalol


Biological context of sotalol


Anatomical context of sotalol


Associations of sotalol with other chemical compounds


Gene context of sotalol


Analytical, diagnostic and therapeutic context of sotalol


  1. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. Mason, J.W. N. Engl. J. Med. (1993) [Pubmed]
  2. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. Roy, D., Talajic, M., Dorian, P., Connolly, S., Eisenberg, M.J., Green, M., Kus, T., Lambert, J., Dubuc, M., Gagné, P., Nattel, S., Thibault, B. N. Engl. J. Med. (2000) [Pubmed]
  3. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. Mason, J.W. N. Engl. J. Med. (1993) [Pubmed]
  4. Sotalol. Hohnloser, S.H., Woosley, R.L. N. Engl. J. Med. (1994) [Pubmed]
  5. Controlled trial of sotalol for one year after myocardial infarction. Julian, D.G., Prescott, R.J., Jackson, F.S., Szekely, P. Lancet (1982) [Pubmed]
  6. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group. Singh, B.N., Kehoe, R., Woosley, R.L., Scheinman, M., Quart, B. Am. Heart J. (1995) [Pubmed]
  7. Effects of the beta-adrenoceptor blocking agent sotalol on CNS: sleep, EEG, and psychophysiological parameters. Bender, W., Greil, W., Rüther, E., Schnelle, K. Journal of clinical pharmacology. (1979) [Pubmed]
  8. Amnesia due to beta-antagonists in a passive avoidance task in the chick. Stephenson, R.M., Andrew, R.J. Pharmacol. Biochem. Behav. (1981) [Pubmed]
  9. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. Pacifico, A., Hohnloser, S.H., Williams, J.H., Tao, B., Saksena, S., Henry, P.D., Prystowsky, E.N. N. Engl. J. Med. (1999) [Pubmed]
  10. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Ho, D.S., Zecchin, R.P., Richards, D.A., Uther, J.B., Ross, D.L. Lancet (1994) [Pubmed]
  11. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Juul-Möller, S., Edvardsson, N., Jahnmatz, B., Rosén, A., Sørensen, S., Omblus, R. Lancet (1992) [Pubmed]
  12. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Juul-Möller, S., Edvardsson, N., Rehnqvist-Ahlberg, N. Circulation (1990) [Pubmed]
  13. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. Wang, J., Bourne, G.W., Wang, Z., Villemaire, C., Talajic, M., Nattel, S. Circulation (1993) [Pubmed]
  14. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Böcker, D., Haverkamp, W., Block, M., Borggrefe, M., Hammel, D., Breithardt, G. Circulation (1996) [Pubmed]
  15. Effect of sotalol on normal intraocular pressure. Crick, R.P., Reynolds, P. Lancet (1980) [Pubmed]
  16. Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase. Cobbe, S.M., Hoffman, E., Ritzenhoff, A., Brachmann, J., Kübler, W., Senges, J. Circulation (1983) [Pubmed]
  17. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Funck-Brentano, C., Kibleur, Y., Le Coz, F., Poirier, J.M., Mallet, A., Jaillon, P. Circulation (1991) [Pubmed]
  18. Sex difference in risk of torsade de pointes with d,l-sotalol. Lehmann, M.H., Hardy, S., Archibald, D., quart, B., MacNeil, D.J. Circulation (1996) [Pubmed]
  19. Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. Oudijk, M.A., Ruskamp, J.M., Ververs, F.F., Ambachtsheer, E.B., Stoutenbeek, P., Visser, G.H., Meijboom, E.J. J. Am. Coll. Cardiol. (2003) [Pubmed]
  20. Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. Senges, J., Lengfelder, W., Jauernig, R., Czygan, E., Brachmann, J., Rizos, I., Cobbe, S., Kübler, W. Circulation (1984) [Pubmed]
  21. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Nademanee, K., Feld, G., Hendrickson, J., Singh, P.N., Singh, B.N. Circulation (1985) [Pubmed]
  22. Identification of a specific radioligand for the cardiac rapidly activating delayed rectifier K+ channel. Chadwick, C.C., Ezrin, A.M., O'Connor, B., Volberg, W.A., Smith, D.I., Wedge, K.J., Hill, R.J., Briggs, G.M., Pagani, E.D., Silver, P.J. Circ. Res. (1993) [Pubmed]
  23. The hemodynamic effects of sotalol and quinidine: analysis by use of rest and exercise gated radionuclide angiography. Mahmarian, J.J., Verani, M.S., Hohmann, T., Hill, R., Thornton, B.C., Bolli, R., Young, J.B., Roberts, R., Pratt, C.M. Circulation (1987) [Pubmed]
  24. Inhibition of sympathetic preganglionic neurons by catecholamines and clonidine: mediation by an alpha-adrenergic receptor. Guyenet, P.G., Cabot, J.B. J. Neurosci. (1981) [Pubmed]
  25. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. Bänsch, D., Castrucci, M., Böcker, D., Breithardt, G., Block, M. J. Am. Coll. Cardiol. (2000) [Pubmed]
  26. Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. Klingenheben, T., Grönefeld, G., Li, Y.G., Hohnloser, S.H. J. Am. Coll. Cardiol. (2001) [Pubmed]
  27. Treatment strategies for atrial fibrillation. Jung, F., DiMarco, J.P. Am. J. Med. (1998) [Pubmed]
  28. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. Fedida, D., Orth, P.M., Hesketh, J.C., Ezrin, A.M. J. Cardiovasc. Electrophysiol. (2006) [Pubmed]
  29. Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs. Kühlkamp, V., Mermi, J., Mewis, C., Braun, U., Seipel, L. Eur. Heart J. (1995) [Pubmed]
  30. Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor. Pickles, H., Perucca, E., Fish, A., Richens, A. Clin. Pharmacol. Ther. (1981) [Pubmed]
  31. Induction of glutamine synthetase by dibutyryl cyclic AMP in C-6 glioma cells. Browning, E.T., Nicklas, W.J. J. Neurochem. (1982) [Pubmed]
  32. Adrenergic and nonadrenergic regulation of hindlimb blood flow during stress in rats. Alper, R.H., Zink, M.H. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  33. Sotalol in patients with Wolff-Parkinson-White syndrome. Kunze, K.P., Schlüter, M., Kuck, K.H. Circulation (1987) [Pubmed]
WikiGenes - Universities